Measurement of Distinct Biological Pools of Hydrogen Sulfide in Women With Cardiovascular Disease

Completed

• Conditions: Cardiovascular Disease

• Registration Number: NCT02180074
• Lead Sponsor: Louisiana State University Health Sciences Center Shreveport

Brief Summary

Cardiovascular disease which includes coronary artery disease and peripheral artery disease remains the leading cause of death among women in the United States. The impact of cardiovascular in women was not recognized by clinicians for a long time. It is now evident that, women suffer the consequences of cardiovascular at rates at least as high as those observed in men but there are still major gaps in our understanding this disease in women. Hydrogen sulfide (H2S), a gaseous mediator plays an important role in the cardiovascular system. Research has demonstrated it's critical role in animal ischemia reperfusion models. Hydrogen sulfide exists in distinct biological pools in blood. Recently, the Kevil lab has pioneered the development of new analytical techniques for accurate measurement of all biological pools of H2S. By measuring these distinct pools of H2S in women with and without cardiovascular disease the investigators hope to further understanding of role of H2S in pathophysiology of cardiovascular disease. This research will help to assess the ability of H2S and its distinct biological pools to potentially be a diagnostic marker or a therapeutic target for cardiovascular disease.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-09
• Study First Submitted: 2014-03-18
• Status Verified: 2014-06
• Study First Submitted QC: 2014-06-30
• Study First Posted: 2014-07-02
• Primary Completion: 2017-05-07
• Study Completion: 2017-05-07
• Last Update Submitted: 2021-08-30
• Last Update Posted: 2021-09-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 137

Inclusion Criteria

1. Patients presenting to the cardiac catheterization laboratory for coronary or peripheral angiography.
2. Females,Age>40years

Exclusion Criteria

1. Inability to provide informed consent.

2. STelevationmyocardialinfarction.

3. Cardiogenicshock.

4. ABI >1.4 (indicative of non-compressible vessel needing further evaluation to diagnose PAD), unless documented known PAD. 4. Non-atheroscleroticPAD(e.g.Buerger'sdisease). 5. Enrolment in another clinical trial with use of experimental therapeutic agents.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Free Sulfide, Bound Sulfide and Acid Labile Sulfide	1 year	Unit of Measure: nMol

Trial Locations

Locations (1)

LSUHSC; 🇺🇸 Shreveport, Louisiana, United States